Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   Terminated · Phase 1 · Cancer - Acute Myeloid Leukemia

   NCT03484520 · AbbVie Inc. · 1 U.S. investigator

   $3,900research payments

2. ClotTriever Outcomes (CLOUT) Registry

   Completed · Deep Vein Thrombosis Leg

   NCT03575364 · Stryker Corporation · 1 U.S. investigator

   $3,893research payments

3. WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

   Recruiting · Not applicable · Stroke, Acute

   NCT04701684 · Philips North America LLC · 1 U.S. investigator

   $3,862research payments

4. An Observational Study on Teriflunomide-exposed Pregnancies

   Completed · Multiple Sclerosis

   NCT03198351 · Genzyme Corporation · 0 U.S. investigators

   $3,780research payments

5. A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

   Completed · Phase 3 · Glabellar Lines

   NCT05248880 · AbbVie Inc. · 1 U.S. investigator

   $3,758research payments

6. Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

   Completed · Phase 4 · Cystic Fibrosis

   NCT05069597 · AbbVie Inc. · 6 U.S. investigators

   $3,757research payments

7. Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

   Completed · Phase 4 · Type 2 Diabetes Mellitus

   NCT05114590 · Sanofi-aventis U.S. LLC · 0 U.S. investigators

   $3,750research payments

8. A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

   Active, not recruiting · Phase 3 · B-Cell Non-Hodgkin Lymphoma (B-NHL)

   NCT06230224 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

   $3,740research payments

9. A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

   Completed · Phase 3 · Rheumatoid Arthritis (RA)

   NCT03086343 · AbbVie Inc. · 3 U.S. investigators

   $3,702research payments

10. A Study of Baricitinib (LY3009104) in Children With COVID-19

    Terminated · Phase 3 · Covid19

    NCT05074420 · Eli Lilly and Company · 2 U.S. investigators

    $3,575research payments

11. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

    Active, not recruiting · Not applicable · Ischemic Stroke

    NCT05478304 · Atricure, Inc. · 1 U.S. investigator

    $3,565research payments

12. Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

    Recruiting · AAA - Abdominal Aortic Aneurysm

    NCT06218875 · W. L. Gore & Associates, Inc. · 1 U.S. investigator

    $3,523research payments

13. Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs

    Completed · Not applicable · Atrial Septal Defect

    NCT02985684 · W. L. Gore & Associates, Inc. · 2 U.S. investigators

    $3,500research payments

14. A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

    Completed · Phase 4 · Uterine Fibroids

    NCT03886220 · AbbVie Inc. · 1 U.S. investigator

    $3,500research payments

15. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    Recruiting · Phase 2 · Lymphoma

    NCT07015242 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $3,479research payments

16. Pediatric Arthritis Study of Certolizumab Pegol

    Completed · Phase 3 · Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

    NCT01550003 · UCB GmbH · 2 U.S. investigators

    $3,470research payments

17. A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

    Completed · Phase 3 · Growth Hormone Deficiency

    NCT04615273 · Ascendis Pharma Endocrinology Inc · 1 U.S. investigator

    $3,437research payments

18. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    Recruiting · Phase 2 · Bipolar Disorder

    NCT07286175 · Eli Lilly and Company · 1 U.S. investigator

    $3,406research payments

19. Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

    Completed · Phase 2 · Dry Eye Disease

    NCT07264517 · Instituto Grifols, S.a. · 1 U.S. investigator

    $3,375research payments

20. A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

    Completed · Phase 3 · Dry Eye Disease

    NCT07284381 · AbbVie Inc. · 11 U.S. investigators

    $3,284research payments

21. Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

    Terminated · Phase 4 · Substance Use Disorders

    NCT05521880 · Melinta Therapeutics, LLC · 1 U.S. investigator

    $3,262research payments

22. Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

    Terminated · Phase 1 · Multiple Myeloma

    NCT02400242 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $3,200research payments

23. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

    Recruiting · Phase 2 · Epithelial Ovarian Cancer

    NCT06890338 · AbbVie Inc. · 2 U.S. investigators

    $3,200research payments

24. A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

    Completed · Phase 3 · Type 2 Diabetes

    NCT02963766 · Eli Lilly and Company · 1 U.S. investigator

    $3,196research payments

25. Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

    Active, not recruiting · Phase 3 · Chikungunya Virus Infection

    NCT04838444 · Valneva Austria GmbH · 3 U.S. investigators

    $3,044research payments

26. A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

    Completed · Phase 1 · Relapsed/Refractory Aggressive B-Cell Lymphoma

    NCT02651662 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $3,025research payments

27. A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection

    Completed · Phase 2 · HIV Infections

    NCT00002086 · AbbVie Inc. · 1 U.S. investigator

    $3,000research payments

28. Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

    Completed · Phase 2, Phase 3 · Sphingomyelin Lipidosis

    NCT02004691 · Genzyme Corporation · 0 U.S. investigators

    $3,000research payments

29. IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

    Terminated · Phase 4 · Heart Failure

    NCT07053475 · American Regent · 1 U.S. investigator

    $3,000research payments

30. Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

    Completed · Phase 1 · Influenza

    NCT06118151 · Sanofi Pasteur Inc. · 1 U.S. investigator

    $2,968research payments

31. RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)

    Recruiting · Cardiac Arrythmias

    NCT03053141 · Boston Scientific Corporation · 1 U.S. investigator

    $2,908research payments

32. Tritanium® Primary Acetabular Shell Study

    Terminated · Not applicable · Arthroplasty, Replacement, Hip

    NCT01063751 · Stryker Corporation · 1 U.S. investigator

    $2,880research payments

33. Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

    Active, not recruiting · Phase 2 · Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

    NCT04430179 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $2,864research payments

34. A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

    Recruiting · Phase 2 · Severe Hypertriglyceridemia

    NCT07269210 · Eli Lilly and Company · 9 U.S. investigators

    $2,817research payments

35. A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

    Completed · Phase 1, Phase 2 · Neoplasms by Site

    NCT03656718 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $2,805research payments

36. Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

    Approved for marketing · Leukemia, Lymphocytic, Chronic, B-Cell

    NCT05172700 · Eli Lilly and Company · 8 U.S. investigators

    $2,772research payments

37. A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

    Active, not recruiting · Phase 2, Phase 3 · Pancreatic Ductal Adenocarcinoma

    NCT07076121 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $2,762research payments

38. Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

    Completed · Not applicable · Peripheral Arterial Disease

    NCT03241459 · Surmodics, Inc. · 1 U.S. investigator

    $2,760research payments

39. A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

    Completed · Phase 1, Phase 2 · Seasonal Influenza

    NCT05827068 · ModernaTX, Inc. · 2 U.S. investigators

    $2,758research payments

40. Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

    Completed · Phase 3 · Retinopathy of Prematurity

    NCT04101721 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $2,750research payments

41. A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Terminated · Phase 2 · Non Small Cell Lung Cancer

    NCT05513703 · AbbVie Inc. · 2 U.S. investigators

    $2,746research payments

42. KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

    Terminated · Phase 2 · System

    NCT03919799 · Sanofi US Services Inc. · 1 U.S. investigator

    $2,715research payments

43. A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

    Completed · Phase 3 · Atopic Dermatitis

    NCT02395133 · Genzyme Corporation · 0 U.S. investigators

    $2,668research payments

44. An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

    Completed · Glaucoma, Open-Angle

    NCT04872348 · Sight Sciences, Inc. · 2 U.S. investigators

    $2,635research payments

45. Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

    Completed · Phase 3 · Methicillin-Resistant Staphylococcus Aureus

    NCT02814916 · AbbVie Inc. · 1 U.S. investigator

    $2,600research payments

46. PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

    Recruiting · Phase 1 · Neuroblastoma

    NCT04837547 · Caris Mpi, Inc. · 1 U.S. investigator

    $2,600research payments

47. A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

    Active, not recruiting · Phase 3 · Primary Biliary Cholangitis

    NCT06730061 · Ipsen Bioscience Inc. · 0 U.S. investigators

    $2,575research payments

48. Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

    Completed · Phase 1 · ADHD

    NCT03103750 · AbbVie Inc. · 0 U.S. investigators

    $2,550research payments

49. Safety of Estrogens in Lupus: Hormone Replacement Therapy

    Terminated · Phase 3 · Systemic Lupus Erythematosus

    NCT00000419 · Chiesi USA, Inc. · 1 U.S. investigator

    $2,541research payments

50. A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

    Active, not recruiting · Not applicable · Mitral Regurgitation Functional

    NCT04147884 · Boston Scientific Corporation · 2 U.S. investigators

    $2,533research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.